Group 1 - The core point of the news is the announcement by Chengda Biological (SH 688739) regarding a change in its board secretary position, with Mr. Li Yeji appointed as the new board secretary while Mr. Cui Jianwei continues in other roles [1] - Chengda Biological's revenue composition for the year 2024 is entirely from biopharmaceuticals, accounting for 100.0% [1] - As of the announcement, Chengda Biological has a market capitalization of 11.9 billion yuan [1]

证券代码：688739 证券简称：成大生物 公告编号：2025-037 辽宁成大生物股份有限公司 关于变更公司董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、提前离任的基本情况 | 姓名 | 离任职 | 离任时 | | 原定任 | 离任 是否继续 | | 具体职务 | 是否存 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 务 | | 间 | 期到期 | 原因 | 在上市公 | | 在未履 | | | | | 日 | | 司及其控 | | 行完毕 | | | | | | | | 股子公司 | | 的公开 | | | | | | | | 任职 | | 承诺 | | | | | | | | 工作 | 董事、副 | | | | | 董事会 | | 2025 | 2026 | | | | | | | 崔建伟 | | | | 职责 是 | 总经理、 | | 否 | | | 秘书 | | 年7月 | 年5月 | | | | | | ...

Group 1 - The company announced the appointment of Mr. Li Yeji as the secretary of the board of directors [2]

Group 1 - The company announced that Mr. Cui Jianwei will no longer serve as the Secretary of the Board due to adjustments in work responsibilities, but will continue in his roles as Director, Deputy General Manager, and Chief Financial Officer [2] - Mr. Li Yeji has been appointed as the new Secretary of the Board following the nomination by the Chairman and approval by the Board Nomination Committee [2] - The company's revenue composition for the year 2024 is entirely from biopharmaceuticals, accounting for 100.0% of the total revenue [3]

证券代码：688739 证券简称：成大生物 公告编号：2025-037 辽宁成大生物股份有限公司 关于变更公司董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、提前离任的基本情况 | | 崔建伟 | | | | 姓名 | | --- | --- | --- | --- | --- | --- | | 秘书 | | 董事会 | | 务 | 离任职 | | 年 月 7 | | 2025 | | 间 | 离任时 | | 年 月 5 | | 2026 | 日 | 期到期 | 原定任 | | 调整 | 职责 | 工作 | | 原因 | 离任 | | | 是 | | 司及其控 股子公司 任职 | 在上市公 | 是否继续 | | 财务总监 | 总经理、 否 | 董事、副 | 行完毕 的公开 承诺 | 在未履 | 具体职务 是否存 | 二、离任对公司的影响 辽宁成大生物股份有限公司（以下简称"公司"）崔建伟先生因工作职责调 整原因，不再担任公司董事会秘书职务，仍继续担任公司董事、副总经理及财务 总监职务。崔 ...

Core Insights - The average premium of the latest closing prices of listed Sci-Tech Innovation Board stocks compared to their issue prices is 111.81%, with 153 stocks experiencing a decline in value [1][2][3] Group 1: Premium and Discount Analysis - Among the 589 listed Sci-Tech Innovation Board stocks, 436 stocks have a closing price higher than their issue price, while 153 stocks have fallen below their issue price [1][2] - The stock with the highest premium is Shuangwei New Materials, with a closing price that is 3361.58% higher than its issue price [1] - The stock with the largest decline is Wanrun New Energy, which has a closing price that is 77.89% lower than its issue price of 299.88 yuan [1][2] Group 2: Notable Stocks with Significant Discounts - Other notable stocks with significant discounts include: - ST Pava, with a discount of 76.37% from its issue price of 51.88 yuan [1][2] - Chengda Biology, with a discount of 71.00% from its issue price of 110.00 yuan [2] - Tianyi New Materials, with a discount of 64.21% from its issue price of 20.37 yuan [2] Group 3: Industry Performance Metrics - The average issue price earnings ratio for Wanrun New Energy is 75.25 times, significantly higher than the industry average of 19.21 times [1] - ST Pava has an issue price earnings ratio of 93.68 times, compared to the industry average of 29.25 times [1]

Summary of Key Points Core Viewpoint - The average premium of the latest closing prices of listed stocks on the Sci-Tech Innovation Board is 107.86% compared to their issue prices, with 159 stocks experiencing a decline in value, indicating a significant number of stocks have broken their issue prices [1]. Group 1: Premium and Discount Analysis - Among the 589 listed stocks, 430 stocks have a closing price that exceeds their issue price, with the highest premium being 3159.68% for Shangwei New Materials [1]. - The stocks with the largest discounts include Wanrun New Energy, which has a discount of 77.76%, and ST Pava, with a discount of 76.07% [1][2]. - The average premium indicates strong market performance for the majority of stocks, while the presence of 159 stocks that have broken their issue prices suggests potential concerns in specific sectors [1][2]. Group 2: Specific Stock Performance - Wanrun New Energy, listed on September 29, 2022, has an issue price of 299.88 yuan and a latest closing price of 43.97 yuan, reflecting a discount of 77.76% [2]. - ST Pava, listed on September 19, 2022, has an issue price of 51.88 yuan and a latest closing price of 10.24 yuan, resulting in a discount of 76.07% [2]. - Other notable stocks with significant discounts include Chengda Biology at 71.05%, Tianyi New Materials at 64.21%, and *ST Guandian at 62.31% [2][3].

Core Viewpoint - The Xiamen Securities Regulatory Bureau has disclosed three administrative penalty decisions related to securities professionals engaging in illegal trading activities, highlighting a broader crackdown on such violations across the industry in 2024 [1][4]. Group 1: Administrative Penalties - Three individuals from Longcheng Guorui Securities and Jinyuan Tongyi Securities were penalized for illegal trading activities, with penalties including fines and confiscation of illegal gains [2][4]. - Zheng Han, born in 1973, incurred a total transaction amount of 5.7667 million yuan with a loss of 48,600 yuan, resulting in a fine of 40,000 yuan due to no illegal gains [2][3]. - Chen Zhongbin, born in 1986, had a transaction amount of 1.9246 million yuan with a profit of 4,069.91 yuan, leading to confiscation of the profit and a fine of 40,000 yuan [2][3]. - Wang Jian, born in 1995, had a transaction amount of 9.7917 million yuan with a profit of 5,579.29 yuan, also facing confiscation of the profit and a fine of 40,000 yuan [2][3]. Group 2: Regulatory Actions - In 2024, the regulatory authorities intensified their crackdown on illegal trading by securities professionals, with 59 cases of violations being addressed across the industry [4]. - A total of 10 administrative penalties were issued in the first half of 2025, involving various securities firms including Zhongshan Securities, Guodu Securities, and others [4]. - The penalties affected not only regular employees but also department heads and senior management, indicating a comprehensive approach to enforcement [4]. Group 3: Specific Cases - Yang Jiangquan, a former executive at Guodu Securities, was fined 150,000 yuan for holding and selling shares of Chengda Biological, resulting in a loss of 1.309 million yuan [5].

Group 1 - Multiple listed companies announced share repurchase plans or progress on June 17, coinciding with the one-year anniversary of the "Science and Technology Innovation Board Eight Articles" [1] - Eight companies from the Science and Technology Innovation Board, including Guoda Materials and Huahai Qingke, proposed share repurchases, indicating a commitment to enhancing quality and returns [1] - Guoda Materials' chairman proposed a repurchase of A-shares using 200 million to 400 million yuan in special loans and self-raised funds, aimed at employee stock ownership plans or convertible bonds [1] Group 2 - Midea Group announced its first share repurchase under a new plan, buying back 2.0781 million shares at a total cost of 150 million yuan, with a future plan to repurchase between 5 billion to 10 billion yuan [2] - Tencent Holdings repurchased 980,000 shares for 500 million HKD, with prices ranging from 507 to 514 HKD per share [2] - As of this year, listed companies have repurchased a total of 71.71 billion yuan, with nine companies, including Kweichow Moutai and Ningde Times, repurchasing over 1 billion yuan each [2]

辽宁成大生物股份有限公司 证券代码：688739 证券简称：成大生物 公告编号：2025-036 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内披露截至上月末的回购进展情况。公司回购股份的进展情况如下：截至 2025 年 6 月 30 日，公司尚未实施本次股份回购计划，公司后续将根据市场情况择机实 施本次回购计划。 三、其他事项 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 | 6 | 月 | 19 | 日~2026 | 年 | 月 | 18 | 日 | | 预计回购金额 | 1,000 万元~2,000 | ...